Oncologic efficacy of Radiofrequency Ablation for Small Renal Masses: Clear Cell versus Papillary Subtype (original) (raw)

The Journal of urology, 2015

Abstract

Current RFA series do not distinguish renal cell carcinoma (RCC) subtypes when reporting oncologic efficacy. Papillary neoplasms may be more amenable to radiofrequency ablation (RFA) than clear cell carcinoma because they are less vascular which may limit heat energy loss. We report the long-term outcomes of patients treated with radiofrequency ablation for small renal masses (SRM) by RCC subtypes. Patients undergoing RFA for SRM (cT1a) at two institutions from March 2007-July 2012 were retrospectively reviewed. Patients were included if they had biopsy confirmed clear cell or papillary RCC histology. Patients had at least one contrast enhanced cross-sectional image following RFA. Demographic data between tumor subtypes were compared using the paired t-test. Oncologic outcomes were determined using Kaplan-Meier survival analysis, and survivor curves were compared using the log rank test. 229 patients met inclusion criteria. There were 181 clear cell tumors and 48 papillary tumors. M...

Clayton Trimmer hasn't uploaded this paper.

Let Clayton know you want this paper to be uploaded.

Ask for this paper to be uploaded.